EROL KELEŞ, Mehmet Erkan KAPLAMA, Bengü ÇOBANOĞLU, İrfan ORHAN

Bifosfonat Kullanımına Bağlı Maksillada Osteonekroz: Olgu Sunumu

Bifosfonatlar meme, prostat ve akciğer kanserlerine bağlı gelişen hiperkalseminin ve multipl myelomaya bağlı metastatik osteolitik lezyonların tedavisinde yaygın olarak kullanılmaktadır. Bifosfonatların en önemli yan etkilerinden biri mandibula ve maksillada yaptığı osteonekrozdur. Bu makalede, yaklaşık 6 ay önce sol üst 2. molar diş çektirme öyküsü olan, muayenesinde oroantral fistül tespit edilen ve kemik metastazı yapmış prostat kanseri nedeniyle bifosfonat kullanan 64 yaşında erkek hasta sunuldu.

Maxillary Osteonecrosis Related to Bisphosphonate Use: A Case Report

Bisphosphonates are widely used in the treatment of hypercalcemia associated with breast, prostate or lung cancer and the metastatic osteolytic lesions of multiple myeloma. One of the most significant side effects of bisphosphonates is the occurrence of osteonecrosis of the maxilla and the mandible. In this case report, we presented a 64 year-old male patient who was receiving bisphosphonates for bone metastasis of prostate cancer with a history of approximately six months ago left upper second molar extraction and a physical examination finding of oroantral fistula.

PDF

___

1. Van Poznak C, Estilo C. Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates. Oncology 2006; 20: 1053-1062.
2. Alıcı S, Çekici S. Malign hastalıklarda bisfosfonatların rolü. Van Tıp Dergisi 2002; 9: 66-72.
3. Duman AE, Güven GS, Gürlek A. Erkek osteoporozu. Hacettepe Tıp Dergisi 2005; 36: 175-183.
4. Benhamou CL. Effects of osteoporosis medications on bone quality. Joint Bone Spine 2007; 74: 39-47.
5. Woo SK, Hellstein JW, Kalmar JR. Systematic review: Bisphosphonates and osteonecrosis of the jaws. Ann Inter Med 2006; 144: 753-61.
6. Akarslan Z, Kahraman S. Kemik metastazı yapmış prostat kanser tedavisinde kullanılan bifosfonata bağlı olarak çene kemiklerinde gelişen osteonekroz : vaka raporu ve literatür derlemesi. Atatürk Üniv Diş Hek Fak Derg 2008; 3: 105-110.
7. Marx RE, Cillo JE, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007; 65: 2397-410.
8. Reid IR, Bolland MJ, Grey AB. Is bisphosphonateassociated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 2007; 41: 318-20.
9. Landesberg R, Cozin M, Cremers S et al. Inhibition of Oral Mucosal Cell Wound Healing by Bisphosphonates. J Oral Maxillofac Surg 2008; 66: 839-47.
10. Naidu A, Dechow PC, Spears R et al. The effects od bisphosphonates on osteoblasts in vitro. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 106: 5-13.
11. Montebugnoli L, Felicetti L, Gissi BD et al. Biphosphonateassociated osteonecrosis can be controlled by nonsurgical management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 104: 473-477.
12. Lehrer S, Montazem A, Ramanathan L et al. Bisphosphonate- Induced Osteonecrosis of the Jaws, Bone markers, and a Hypothesized Candidate Gene. J Oral Maxillofac Surg 2009; 67: 159-161.
13. Leite AF, Figueiredo PT, Melo NS et al. Bisphosphonate associated osteonecrosis of the jaws. Report of a case and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102: 14-21.
14. Gutta R, Louis PJ. Bisphosphonates and osteonecrosis of the jaws: Science and rationale. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 104: 186-193.
15. Song K, Min Y, Lee J et al. A Probable Case of Oral Bisphosphonate-Associated Osteonecrosis of the Jaw and recovery with Parathyroid Hormone Treatment. Current Therapeutic Research 2008; 69: 356-362.